| Overview |
| bs-5949R-PE |
| RNF56 Polyclonal Antibody, PE Conjugated |
| WB |
| Human |
| Mouse, Rat, Dog, Cow, Pig, Horse, Chicken |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human RNF56/CBL-B |
| 101-200/982 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 868 |
| Q13191 |
| Cytoplasm, Nucleus |
| Cbl-b; RNF56; Nbla00127; E3 ubiquitin-protein ligase CBL-B; Casitas B-lineage lymphoma proto-oncogene b; RING finger protein 56; SH3-binding protein CBL-B; Signal transduction protein CBL-B; CBLB |
| E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. Slightly promotes SRC ubiquitination. May be involved in EGFR ubiquitination and internalization. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz